Ameritas Investment Partners’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $318K | Hold |
1,594
| – | – | 0.01% | 1013 |
|
|
2025
Q4 | $301K | Hold |
1,594
| – | – | 0.01% | 1025 |
|
|
2025
Q3 | $282K | Sell |
1,594
-354
| -18% | -$52.6K | 0.01% | 1048 |
|
|
2025
Q2 | $221K | Buy |
1,948
+137
| +8% | +$14.6K | 0.01% | 1235 |
|
|
2025
Q1 | $190K | Hold |
1,811
| – | – | 0.01% | 1288 |
|
|
2024
Q4 | $194K | Buy |
1,811
+155
| +9% | +$17.5K | 0.01% | 1344 |
|
|
2024
Q3 | $166K | Hold |
1,656
| – | – | 0.01% | 1442 |
|
|
2024
Q2 | $140K | Hold |
1,656
| – | – | ﹤0.01% | 1510 |
|
|
2024
Q1 | $121K | Hold |
1,656
| – | – | ﹤0.01% | 1614 |
|
|
2023
Q4 | $118K | Hold |
1,656
| – | – | ﹤0.01% | 1625 |
|
|
2023
Q3 | $99.2K | Buy |
1,656
+279
| +20% | +$18.4K | ﹤0.01% | 1662 |
|
|
2023
Q2 | $99.3K | Buy |
1,377
+158
| +13% | +$11.9K | ﹤0.01% | 1608 |
|
|
2023
Q1 | $89.7K | Hold |
1,219
| – | – | ﹤0.01% | 1607 |
|
|
2022
Q4 | $86.7K | Sell |
1,219
-735
| -38% | -$47.8K | ﹤0.01% | 1700 |
|
|
2022
Q3 | $104K | Hold |
1,954
| – | – | ﹤0.01% | 1463 |
|
|
2022
Q2 | $108K | Hold |
1,954
| – | – | ﹤0.01% | 1451 |
|
|
2022
Q1 | $137K | Hold |
1,954
| – | – | ﹤0.01% | 1426 |
|
|
2021
Q4 | $188K | Hold |
1,954
| – | – | 0.01% | 1263 |
|
|
2021
Q3 | $170K | Sell |
1,954
-7,324
| -79% | -$566K | 0.01% | 1331 |
|
|
2021
Q2 | $759K | Hold |
9,278
| – | – | 0.03% | 699 |
|
|
2021
Q1 | $882K | Buy |
9,278
+112
| +1% | +$10.6K | 0.03% | 641 |
|
|
2020
Q4 | $569K | Sell |
9,166
-351
| -4% | -$20K | 0.03% | 734 |
|
|
2020
Q3 | $566K | Hold |
9,517
| – | – | 0.03% | 683 |
|
|
2020
Q2 | $664K | Sell |
9,517
-316
| -3% | -$20K | 0.03% | 610 |
|
|
2020
Q1 | $446K | Sell |
9,833
-481
| -5% | -$27.3K | 0.03% | 661 |
|
|
2019
Q4 | $671K | Sell |
10,314
-771
| -7% | -$51.5K | 0.03% | 666 |
|
|
2019
Q3 | $688K | Sell |
11,085
-652
| -6% | -$40.9K | 0.03% | 646 |
|
|
2019
Q2 | $836K | Sell |
11,737
-648
| -5% | -$47.7K | 0.04% | 582 |
|
|
2019
Q1 | $971K | Sell |
12,385
-469
| -4% | -$35.5K | 0.05% | 518 |
|
|
2018
Q4 | $1.09M | Buy |
12,854
+10,058
| +360% | +$1.07M | 0.06% | 420 |
|
|
2018
Q3 | $479K | Hold |
2,796
| – | – | 0.02% | 742 |
|
|
2018
Q2 | $361K | Buy |
2,796
+20
| +0.7% | +$2.23K | 0.02% | 809 |
|
|
2018
Q1 | $286K | Sell |
2,776
-108
| -4% | -$10.7K | 0.01% | 913 |
|
|
2017
Q4 | $246K | Hold |
2,884
| – | – | 0.01% | 989 |
|
|
2017
Q3 | $231K | Hold |
2,884
| – | – | 0.01% | 981 |
|
|
2017
Q2 | $218K | Buy |
2,884
+247
| +9% | +$17.3K | 0.01% | 1016 |
|
|
2017
Q1 | $174K | Buy |
+2,637
| New | +$173K | 0.01% | 1136 |
|
Other funds holding LGND
VPM
VCM
NAMI
CC
Ameritas Investment Partners's LGND Position: Q1 2026 in Review
Ameritas Investment Partners held its Ligand Pharmaceuticals (LGND) position steady in Q1 2026 at 1,594 shares worth $318K. The position accounts for 0.01% of the portfolio, ranked #1013.
Ameritas Investment Partners first reported a position in LGND in Q1 2017 and has held it in 37 quarters since. The position peaked at $1.09M in Q4 2018. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.
- Ameritas Investment Partners held 1,594 shares of Ligand Pharmaceuticals worth $318K as of Q1 2026.
- Ameritas Investment Partners left its Ligand Pharmaceuticals share count unchanged in Q1 2026.
- Ligand Pharmaceuticals made up 0.01% of Ameritas Investment Partners's portfolio in Q1 2026, its #1013 holding.
- Ameritas Investment Partners first reported a position in Ligand Pharmaceuticals in Q1 2017 and has held it in 37 quarters since.
- Ameritas Investment Partners's Ligand Pharmaceuticals position peaked at $1.09M in Q4 2018.
- 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.
Based on Ameritas Investment Partners's 13F filing for Q1 2026, filed 13 May 2026.